The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1207
April 25, 2005
View Complete Issue         Table of Contents 2019 
Palifermin (Kepivance) for Myelotoxic-Therapy-Related Mucositis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Palifermin (Kepivance) for Myelotoxic-Therapy-Related Mucositis
April 25, 2005 (Issue: 1207)
Palifermin (Kepivance - Amgen), a recombinant human keratinocyte growth factor (KGF), has been approved by the FDA to decrease the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Palifermin (Kepivance) for Myelotoxic-Therapy-Related Mucositis
Article code: 1207c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.